FEFazilet Erman

Fazilet Erman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fazilet Erman has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epigallocatechin-3-Gallate Activates Nrf-2, NF-κB and TNF-α Protein Signaling Pathways in Rat Muscle Tissue Damage

    by Rumeysa Demiroğlu Yüksek, Fazilet Erman, Seda Beyaz, Özlem Gök, Orhan Erman, İbRahim Hanifi Özercan, Abdullah Aslan

    Cisplatin, used as an effective drug in cancer patients, has become a popular topic in studies conducted in recent years. It is known that cisplatin terminates the vital activities of healthy cells as well as cancer cells. Epigallocatechin-3-gallate (EGCG), a member of the catechin group, is a natural antioxidant known to promote and improve health. Catechins, due to their regulatory effect on apoptosis and autophagy, have attracted increasing interest in their positive health effects on various diseases. This study aims to investigate the effect of EGCG on Nrf-2, NF-κB, and TNF-α protein signaling pathways against muscle tissue damage caused by cisplatin. A total of 28 male rats were used in the study, creating 4 groups. The experimental period was 28 days (4 weeks). The protective and healing effects of EGCG against cisplatin-induced damage in muscle tissue were investigated. Catalase (CAT) activity, malonaldehyde (MDA), and glutathione (GSH) levels were measured in a spectrophotometer. Expression levels of Nrf-2, NF-κB, and TNF-α proteins were determined using the Western blot method. When compared to the cisplatin-administered group, MDA levels decreased in the EGCG+Cisplatin-administered group, while CAT activity and GSH levels increased. It was found that EGCG used for therapeutic purposes reduced the expression of Nrf-2, NF-κB, and TNF-α proteins. Histopathological examination showed that muscle tissue damage occurred in the cisplatin group, while the damage decreased in the EGCG+Cisplatin-administered group. Our findings show that EGCG can prevent toxicity due to its anti-inflammatory effect against tissue damage caused by cisplatin.

  • Ellagic acid inhibits proinflammatory intermediary manufacture by suppressing NF-κB/Akt, VEGF and activating Nrf-2/Caspase-3 signaling pathways in rat testicular damage: a new way for testicular damage cure andin silicoapproach

    by Abdullah Aslan, Ozlem Gok, Seda Beyaz, Harun Uslu, Fazilet Erman, Orhan Erman, Serpil Baspinar

    Ellagic acid (EA) has protective effect on testicular damage and this natural compound decreases oxidative damage. The present study aims to examine the preventive effect of ellagic acid (EA) against carbon tetrachloride (CCl4)-induced testicular tissue damage in rats. In testicular tissue, tumor necrosis factor-α (TNF-α), Nuclear factor erythroid-2 related factor 2 (Nrf-2), B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor (VEGF), Nuclear factor-kappa B (NF-κB), cysteine aspartic proteases (caspase-3) and protein kinase B (Akt) synthesis levels were analyzed by western blot method, reactive oxygen species (ROS) was measured by malondialdehyde (MDA) levels, Glutathione (GSH) level and catalase (CAT) by spectrophotometer. As a result, in comparison with the CCl4 group, caspase-3 and Nrf-2 protein synthesis levels increased in EA + CCl4 group, however, VEGF, Bcl-2, NF-κB, TNF-α and Akt protein synthesis levels decreased, EA application raised GSH levels and CAT activity, reduced MDA levels. In this study, in silico tools were applied to confirm the activity of EA against the cancer with macromolecules such as the above mentioned transcription factors. EA, turned out to show significant activity similarly to some cocrystal ligands, particularly against cancer. These results points out that EA can be used as a testicular damage cure drug in future.


  • Open Access

    Wnt signaling pathway activities may be altered in primary Sjogren’s syndrome

    by Ahmet Karataş, Zühal Ömerci̇kOğlu, Burak Öz, Adile Ferda Dağli, Onur Çatak, Fazilet Erman, Kazım ŞAHİN, Nevzat Gözel, Süleyman Serdar Koca

    Sjögren?s syndrome (SS) is an autoimmune disease and its pathogenesis is still not completely clear. The Wingless (Wnt) / ß - catenin pathway has recently been shown to play an important role in inflammation. This study aims to determine the serum and saliva levels of Dickkopf (DKK)1 and sclerostin and evaluate Wnt-1 and Wnt-3a expression in the salivary gland in patients with primary SS Materials and methods:. This study included 30 patients diagnosed with SS, 30 patients diagnosed with systemic lupus erythematosus (SLE), and 29 healthy controls. Serum and saliva levels of DKK1 and sclerostin were measured and the expressions of Wnt1 and Wnt3a in the salivary gland were measured immunohistochemically. Serum DKK1 and sclerostin levels were lower in the SS and SLE groups compared to the control group (both p < 0.001). Saliva DKK1 levels were higher in the SS group compared to the control and SLE groups (p = 0.004 and p = 0.009, respectively). Wnt1 and Wnt3a expression were found in salivary gland tissue samples in 71.4% of primary SS patients and relatively frequent than control group. Serum DKK1 and sclerostin levels in primary SS and SLE were decreased. Moreover, levels of Wnt1 and Wnt3a expression in the salivary gland were also elevated in primary SS. Therefore, it can be concluded that the Wnt / ß - catenin pathway activities may be altered in case of glandular inflammation.


  • Pemetrexed Ameliorates Experimental Arthritis in Rats

    by Ahmet Karatas, Suleyman Serdar Koca, Metin Ozgen, Adile Ferda Dagli, Fazilet Erman, Nuran Sahin, Kazim Sahin, Ahmet Isik

    Pemetrexed (PMTX) is an anti-folate drug as methotrexate. The purpose of this study was to assess the efficacy of PMTX on collagen-induced arthritis (CIA). Forty Wistar albino rats were randomized into four groups. Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s adjuvant. Animals were sacrificed at the 15th day after the onset of arthritis. Tumor necrosis factor alpha (TNF-α), interleukin (IL)-17, and malondialdehyde (MDA) levels were increased, and superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities and the expressions of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) were decreased in the arthritis group. In the PMTX-treated (0.2 and 1 mg/kg/week i.p.) groups, the levels of TNF-α, IL-17, and MDA were decreased; the activities of SOD, CAT, and GPx and the expressions of Nrf2 and HO-1 were restored, and perisynovial inflammation and cartilage–bone destruction were decreased. PMTX has anti-arthritic potential in the CIA model and may be a therapeutic agent for rheumatoid arthritis.